JDRF and Tandem Diabetes Care, the company behind the t:slim insulin pump, have teamed up to develop a dual-chamber infusion pump for the management of diabetes. The partnership agreement is designed to accelerate the development of a next-generation, fully automated artificial pancreas system.
The Behavorial Diabetes Institute (BDI) Needs Your Help
Sometimes it can be tough and frustrating when you have a partner with type 1 diabetes. …
New research from the University of Pennsylvania has discovered that the most popular type 2 diabetes medication, metformin, works differently than previously thought. Metformin was known to lower blood glucose levels by decreasing the amount of glucose produced by the liver, but how the drug did this was not known.
A group of biomedical researchers at UC Santa Barbara is studying the metabolism of cells and their surrounding tissue, to ferret out ways in which certain diseases begin. This approach, which includes computer modeling, can be applied to type 2 diabetes, autoimmune diseases, and neurodegenerative diseases, among others.
JDRF reported today that Congress has included a $150 million extension of the Special Diabetes Program (SDP) as part of a year-end package of legislation to avert the "fiscal cliff."
"For the past year, we have led the fight in Congress for renewal of the SDP because we know that this program has contributed to remarkable scientific breakthroughs in managing and treating diabetes, and this timely extension is central to curing T1D,"
Want to succeed managing your diabetes? Now you can. Diabetes Do's & How-To's is the quintessential "owner's manual" for those with diabetes and pre-diabetes. Here are the small, yet powerful steps to live well with diabetes -- and guidance how to take them.
The ADA Standards of Medical Care has recommended changes in blood pressure goals for people with diabetes as well as clarifying how frequently people with type 1 diabetes should test their blood glucose levels.
The Japanese Ministry of Health, Labor and Welfare has approved Novo Nordisk's new combination insulin, Ryzodeg, for the treatment of diabetes.
Ryzodeg is a soluble formulation of Tresiba (insulin degludec), a once-daily new-generation basal insulin analogue with an ultra-long duration of action, and NovoRapid (insulin aspart which in the U.S. is marketed under the brand name NovoLog). Ryzodeg can be administered once or twice daily with the main meal(s).
Insulet Corporation, the leader in tubeless insulin pump technology, today announced that the Company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the next-generation OmniPod® Insulin Management System.
Novo Nordisk has announced the initial results of the Diabetes Attitudes, Wishes and Needs 2 (DAWN2) study. The DAWN2 study is the largest study of its kind, conducted across 17 countries and 4 continents, into the psychosocial aspects of management of diabetes.